Cite
HARVARD Citation
DuBois, S. et al. (2021). Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Journal of clinical oncology. 39 (31), pp. 3506-3514. [Online].